Aminoglutethimide was introduced as an anticonvulsant drug in the U.S. A. in 1960. The occurrence of a number of side-effects, including several endocrine effects such as goitrogenesis, sexual precocity and virilization, led to its withdrawal.
purpose of this paper to describe the events leading to the withdrawal of aminoglutethimide and also to review the subsequent biochemical (Lambros, 1958; LaVeck, 1960; Pearce, 1960; Aguilar, Martin & McNaughton, 1961) and the European medical literature (Guareschi, Giannelli & Marinato, 1956; Sheehan, 1958; Fabisch, 1959; Defer, 1960; Verdeau-Pailles, 1961) . All these papers reported varying degrees of efficacy in either grand mal, petit mal or psychomotor epilepsy. Nevertheless, in one study, of 2 years' duration, using aminoglutethimide with other anticonvulsants, it was found to be impossible to discontinue any of the companion drugs (Aguilar et al., 1961) (Iffy et al., 1965 1967) . Furthermore aminoglutethimide had been fed to puppies and these animals had subsequently been shown to be unresponsive to ACTH and studies in rats showed that the drug induced adrenal hypertrophy (Pittman & Brown, 1966) . The systematic biochemical and clinical investigation of the effects of aminoglutethimide on the adrenal glands which followed is reviewed below.
Histological evidence of adrenocortical inhibition
Post-mortem adrenal gland specimens from fourteen patients who had received aminoglutethimide (in addition to one or more other anti-convulsants) were examined. Striking histological changes were seen in ten patients. These included cellular hypertrophy, cytoplasmic vacuolation and excessive accumulation of lipid in the cortex of the glands . Similar findings have been described more recently by Givens, Coleman & Britt (1968) who administered aminoglutethimide (750-1000 mg/day) to four adults awaiting adrenalectomy. Three patients had metastatic carcinoma of the breast, two were euadrenal and one was receiving a suppressive dose of prednisolone. The fourth patient had metastatic non-functioning adrenocortical carcinoma. The anatomical changes found in the euadrenal subjects were: an increase in size and weight of the adrenal glands, a marked golden-yellow colour, an increased size of the zona fasciculata, marked diminution in the size of the zona glomerulosa and an increase in the lipid-positive staining deposits in the cells of the zona fasiculata. The latter observation was also present in the patient receiving prednisolone. Similar changes have also been demonstrated in rats and puppies receiving aminoglutethimide .
Mechanism of adrenocortical inhibition
Experimental studies undertaken by Wilroy, Camacho & Trouy (1966) in rats and dogs, the additional work in rats and the in vitro studies of Dexter et al. (1966 and 1967) , have shown that aminoglutethimide produces a decrease in corticosterone production which is accompanied by an increase in plasma ACTH. Marked hypertrophy of the adrenals occurs, this being due to both the adrenal growth-promoting effect of the increased endogenous ACTH and also to the increased water, cholesterol and cholesterol esters found in the glands. There was no evidence to suggest that the conversion of pregnenolone to corticosterone was impaired and it was, therefore, concluded from these studies that the drug inhibits conversion of cholesterol to pregnenolone and that the accumulation of cholesterol in the adrenal glands can be attributed to the combined effects of the increased endogenous ACTH and a direct action of the drug. Cash et al. (1967) (Sheppard, Beasley & Wacker, 1966) .
Experimental studies in humans followed as a logical extension of the in vitro studies and work in animals. Camacho et al. (1967) and Cash et al. (1967) showed that the inhibitory effect of aminoglutethimide on steroidogenesis blocks the production of adrenal cortisol, aldosterone and androgens and also their hormonally active precursors. These findings were confirmed by (Horky & Kichel, 1969 (Livingstone, 1956) , hirsutism (Livingstone, Petersen & Boks, 1955) and hypertrichosis, brown pigmentation and acne (Bray, 1959 Glutethimide was also included in the series of glutarimides examined in vitro by Kahnt & Neher (1966) , for effects on corticosteroid synthesis. This particular work showed that a hydrazide derivative, known as CIBA 17368-Ba, in a concentration of 6 pug/ml completely blocked corticosteroid synthesis by inhibition of 20-hydroxylation of cholesterol. Para-aminoglutethimide and ortho-aminoglutethimide produced similar inhibition at a concentration of 30 jxg/ml but concentrations of 60 jig/ml of both glutethimide and phenglutethimide failed to have any effect. Phenytoin and the barbiturates were also included in this work and also failed to have any effect. Cohen (1968) (Keberle, 1962) and aminoglutethimide (Douglas & Nicholls, 1965) , in man, suggests that the metabolism of these two drugs may differ significantly.
The clinical literature of phenglutarimide, a parasympatholytic substance in limited use for controlling disorders of extra-pyramidal origin affecting muscular tonus and motor function, contains no references to endocrinological side-effects. The future for aminoglutethimide
The experimental studies previously cited indicate that the most important single action of aminoglutethimide is the inhibition of adrenal steroid biosynthesis immediately prior to the production of delta-5 pregnenolone. It would, therefore, seem reasonable to employ aminoglutethimide clinically in patients where it is desirable to block the production of the whole range of adrenal steroids. In practice, however, the main interest has so far been directed to clinical problems in patients with excessive cortisol and aldosterone production.
In most cases of Cushing's disease surgical treatment is satisfactory, but there is a small number where the operation is unsuccessful, only partially successful, or cannot be contemplated because of extensive neoplasia. In such cases treatment with drugs which will block adrenal metabolism is considered.
Hitherto adrenal blockers have comprised such drugs as metyrapone, which inhibits specific pathways of steroid synthesis (Gaunt, Chart & Renzi, 1965) , or toxic agents such as ortho-para-DDD which may produce profound constitutional disturbance (Weisenfeld & Goldner, 1962 
